Tamoxifen Increases the Risk of Microvascular Flap Complications in Patients Undergoing Microvascular Breast Reconstruction

Kelley BP, Valero V, Yi M, et al (The Univ of Texas M. D. Anderson Cancer Ctr, Houston) Plast Reconstr Surg 129:305-314, 2012^§

Abstract

Background

Tamoxifen citrate (tamoxifen) has been associated with increased rates of thromboembolic events, prompting concerns that it may increase the risk of complications after microvascular breast reconstruction. Some centers have implemented protocols to temporarily stop tamoxifen before microvascular breast reconstruction. The authors sought to determine whether this practice is warranted.

Methods

A total of 670 patients underwent delayed microsurgical breast reconstruction at the authors’ institution between January of 2000 and April of 2010. Rates of microvascular flap complications and pulmonary emboli were retrospectively compared between patients who were and were not receiving tamoxifen at the time of reconstruction.

Results

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

Invasive Component Separation Results in Fewer Wound-Healing Complications than Open Component Separation for Large Ventral Hernia Repairs to Basics: Understanding the Terminology Associated With Light- and Energy-Based Technology of Hyperhidrosis With Botulinum Toxin fifteen-year experience of buttock contouring with combination of silicone implant, liposuction, and structural fat grafting Systematic Review and Meta-Analysis of Complications Associated With Acellular Dermal Matrix-Assisted Breast Reconstruction and Tribulations with the Inferior Gluteal Artery Perforator Flap in Autologous Breast Reconstruction

Stay updated, free articles. Join our Telegram channel

Join